Massive UK Moderna partnership

UK cements 10-year-partnership with Moderna in major boost for vaccines and research Moderna to invest in mRNA research and development (R&D) in the UK, and build a state-of-the-art vaccine manufacturing centre, with the ability to produce up to 250 million vaccines a year Suggested advantages NHS patients will have access to a UK-made supply of COVID-19 jabs, as well as cutting-edge vaccines developed for other respiratory diseases, such as flu and respiratory syncytial virus (RSV) Create more than 150 jobs Further future-proof the UK against potential pandemics, speedy access to the latest advancements in vaccine technology UK cements its status as a life sciences superpower. The partnershi
Back to Top